Unequal access to monkeypox shots gives Europe pandemic flashbacks


Flavio Stupino, a bank worker in Milan, had taken the same train many times before — for a vacation, to visit a friend or a lover on the French Côte d’Azur. This time, though, he was crossing the border with a different aim: to get a monkeypox vaccine.

For nearly two months, he had anxiously scrutinized his skin for any sign of infection. He had stopped visiting gay clubs and saunas and refrained from casual sexual encounters. Then Stupino heard that France was offering vaccinations, while Italy still did not.

“I had to run for cover,” he said.

In Europe, the global monkeypox hot spot, the latest outbreak has disturbing echoes of the last one, when stocks of protective gear, coronavirus tests and Covid-19 vaccine were, at first, inadequate, hampered by production bottlenecks, and distributed at uneven speeds.

Once again, some nations are much better equipped than others. And despite a strengthened mechanism for common purchases, they are now competing against one another and against the European Union for limited vaccine supplies, and “vaccine tourism” — crossing borders in search of shots — has returned.

Until the delivery last week of about 7,000 doses supplied by Brussels, Spain, the epicenter of the European monkeypox outbreak, had access to only about 5,000, leaving many vulnerable people still waiting. France, with fewer than half as many confirmed cases, had already vaccinated 27,000 people.

The EU set out to prevent a repeat of the Covid-19 debacle and last year created a new health emergency agency that was supposed to act decisively and put all 27 member countries on an equal footing. But experts say the new agency does not have the full powers envisioned for it, in part because individual countries have been unwilling to cede authority in the politically sensitive area of public health.

In 2020, while Covid-19 vaccines were still in development, the pandemic was already an enormous health and economic crisis, and it was clear that Europe would need billions of doses. Yet the European Commission, the EU executive branch, was slower than the United States or Britain to buy and distribute vaccines, drawing bitter criticism.

When monkeypox first began to spread in Europe in May, the situation was, in many ways, very different: There was no prospect of a wave of fatalities, the disease was not widespread, the containment strategy called for inoculating only certain at-risk people, and vaccines already existed.

Determined not to repeat Covid-19 missteps, the new European agency ordered 110,000 vaccine doses with EU funds in early June. At that point, only 299 cases had been reported in the EU, officials said, and the commission said in a statement that the purchase was sufficient “to cover the most immediate, short-term needs of member states.”

It was not. National health authorities had underestimated how fast the virus would spread, particularly among men who have sex with men. More than 30,000 people have been infected worldwide, and millions are considered at risk.

In addition, only one vaccine is approved in Europe for monkeypox prevention, manufactured by one fairly small pharmaceutical company, Bavarian Nordic, which faces production limitations and has competing orders. About 58,000 doses of the initial EU order two months ago have so far been delivered, with the rest expected by the end of August.

Vaccines for smallpox, once a leading killer, are also effective against monkeypox, and inoculation was nearly universal until the 1970s. But routine vaccination stopped when smallpox was eradicated, and older types of vaccine carry some risks that regulators consider acceptable only when trying to prevent a disease as deadly as smallpox.

European regulators have only approved Bavarian Nordic’s shot — known as Imvanex in Europe, Imvamune in Canada and Jynneos in the United States — as safe enough for monkeypox prevention; two doses are required to be fully vaccinated. That “third generation” vaccine is also approved in the United States, where regulators also recently gave permission to use a second-generation smallpox shot, ACAM2000, for monkeypox.

Individual countries and the World Health Organization have kept stores of smallpox vaccines in case the disease ever returns, but they vary enormously. Some national stockpiles are large enough to vaccinate every resident, while others are far short of that.

Some countries, like the Netherlands, France and the United States, had significant supplies of Bavarian Nordic’s vaccine in their stores before monkeypox struck. Others, like Italy and Spain, did not.

Within weeks of the initial EU order, it became clear that it was not enough, and Brussels increased its purchase to 160,000 doses, the maximum under its emergency procedure — which was still inadequate. As cases mounted, the new European agency entered negotiations — still underway — for a new contract, but by then it was competing with many countries, including EU members, trying to buy on their own.

Spain has reported more than 5,000 monkeypox cases, by far the most in Europe, and has depended almost entirely on the EU mechanism for vaccines, receiving about 15,000 doses so far.

Nahum Cabrera, the HIV coordinator for Spain’s federation of LGBT associations, said that available vaccination spots were always filled in a matter of minutes, and the vast majority of the most vulnerable communities had been left out.

“We are relying on Europe, and this worries us,” he said. “Because Europe is going very slowly.”

The German government ordered 240,000 doses directly from Bavarian Nordic — more than the European Commission has for the continent — of which 40,000 have been delivered. In addition, it has received 5,300 through the commission. Belgium ordered 30,000 doses on its own but so far has received only 3,040 doses from the EU order.

The French Health Ministry said it had both dipped into its vaccine stockpile and made a direct order from Bavarian Nordic, which it declined to describe in detail. Dr. Giovanni Rezza, who is in charge of prevention at Italy’s Health Ministry, said his country had been in talks with the company, but with no conclusion so far.

Jean-Michel Dogné, a professor at the University of Namur in Belgium and adviser to the European Medicines Agency and WHO, said that direct deals might be useful for countries that were hit hardest, but that they carried risks.

“There is no merit in having competition in between member states at the EU level,” he said. “The first aim is really to work together to avoid this.”

Source link


Please enter your comment!
Please enter your name here